Meet the Author

Paul Cranston

Paul analyses the online conversations of HCPs to provide insights for pharmaceutical companies about what HCPs think. With a background in international development, he is passionate about using data to reveal the unmet needs in healthcare communities.

In his free time, Paul can often be found either writing songs on his guitar or kicking a ball around on a football field.

Articles by Paul Cranston

05.02.2023 | Article

Product Launch Tracker: HCPs start the year discussing approvals for Alzheimer’s and…

HCP's in the month of Jan discussed online their thoughts on a new treatment for Alzheimer’s

By Paul Cranston

15.01.2023 | Article

Product Launch Tracker: HCPs discuss pre-Christmas approvals in precision medicine, oncology and…

At the start of the month, HCPs were interested in the first faecal microbiota product

By Paul Cranston

16.12.2022 | Article

Product Launch Tracker: HCPs discuss first drug to delay type 1 diabetes…

In Nov. 2022 HCPs discussed treatments for multiple myeloma, gene therapy and diabetes.

By Paul Cranston

14.11.2022 | Article

Product Launch Tracker: HCPs share optimism for approvals in heart failure, obesity…

HCP's shared the news on product approvals for issues like obesity, multiple myeloma, etc.

By Paul Cranston and Tomi Shobande

06.07.2022 | Article

How HCPs are utilising medical podcasts

Podcasts are popular among HCPs because they bridge the gap between informative and enter...

By Paul Cranston

05.07.2022 | Article

Product Launch Tracker: HCPs discuss approvals including for the prevention of smallpox…

HCPs also held around the approval of treatments for monkeypox

By Paul Cranston and Tomi Shobande

02.07.2022 | Article

Product Launch Tracker: HCPs celebrate 5th agnostic approval in Cancer alongside other…

with notable excitement being found for the FDA’s approval of Novartis’ 5th agnostic...

By Paul Cranston and Tomi Shobande

06.06.2022 | Article

Product Launch Tracker: HCPs excited by approvals for Eli Lilly, Novartis, Sanofi…

Over the last month, HCPs discussed product approvals for the treatment of a variety...

By Paul Cranston and Tomi Shobande

19.05.2022 | Article

Product Launch Tracker: HCPs excited for BMS’ newly approved ‘Camzyos’

Discover which new drug approvals HCPs are talking about

By Paul Cranston and Tomi Shobande

12.04.2022 | Article

Product Launch Tracker: HCPs discuss approvals for several cancer treatments and a…

HCPs discuss approvals for several cancer treatments and a fourth dose of COVID-19 vaccines

By Paul Cranston and Tomi Shobande

29.03.2022 | Article

Why HCPs want more funding for brain tumour research and treatment

Cancerous tumours in the brain and central nervous system (CNS) is the 10th leading cause...

By Paul Cranston

11.03.2022 | Article

Product Launch Tracker: Approvals for Boehringer Ingelheim, Eli Lilly, and Novo Nordisk…

HCPs discuss approvals for Boehringer Ingelheim, Eli Lilly, and Novo Nordisk

By Paul Cranston and Tomi Shobande

09.02.2022 | Article

Product Launch Tracker: HCPs celebrate new treatments for metastatic melanoma and non-small…

HCPs also shared the news of approvals of treatments for NSCLC

By Paul Cranston and Tomi Shobande

10.01.2022 | Article

Product Launch Tracker: Pre-Christmas approvals drive HCPs conversations

Discover which new drug approvals dominated HCPs conversations pre-Christmas...

By Paul Cranston and Tomi Shobande

22.12.2021 | Article

All HCPs want for Christmas is…

Discover what HCPs wanted for Christmas in 2021

By Paul Cranston and Francesca Gan

01.12.2021 | Article

Product Launch Tracker: HCPs welcome approvals for MSD’s Keytruda and Takeda’s Livtencity

Discover which new drug approvals HCPs are talking about

By Paul Cranston and Tomi Shobande